高危肺栓塞患者静脉-动脉体外膜氧合前溶栓的回顾性队列研究
本研究为回顾性队列研究,纳入2012年6月至2023年6月Sorbonne大学三个ICU的72例高危肺栓塞接受VA-ECMO患者,其中31例(43%)在ECMO前接受了全身溶栓(T+组),41例(57%)未接受(T-组)。T+组ECMO前心脏骤停比例更高(94% vs 67%,p=0.02)。90天生存率两组无差异(39% vs 46%,log-rank检验,p=0.31),严重出血发生率无差异(61% vs 59%,p=1)。28例患者中25例在中位69(52-95)个月时随访,长期生活质量可接受,无慢性血栓栓塞性肺动脉高压发生。结论认为近期全身溶栓不应作为高危肺栓塞VA-ECMO的禁忌症。
要点
- 高危肺栓塞患者VA-ECMO前接受全身溶栓与未接受者90天生存率无差异(39% vs 46%,log-rank检验,p=0.31)。
- 两组严重出血发生率无差异(61% vs 59%,p=1)。
- 溶栓组ECMO前心脏骤停比例更高(94% vs 67%,p=0.02)。
- 25/28例患者在中位69(52-95)个月随访时生活质量可接受,无慢性血栓栓塞性肺动脉高压。
- 作者认为,近期全身溶栓作为单一参数不应被视为高危肺栓塞VA-ECMO的禁忌症。
适用人群与场景
- 2012年6月至2023年6月Sorbonne大学三个ICU收治的高危肺栓塞并接受VA-ECMO的患者,中位年龄48(37-61)岁,SAPS II 74(60-85)。
- 分为ECMO前接受全身溶栓组(T+组,31例,43%)和未接受溶栓组(T-组,41例,57%)。
研究设计与关键结果
- 研究类型:回顾性队列研究,三个ICU,纳入72例高危肺栓塞VA-ECMO患者。
- 干预与对照:ECMO前全身溶栓(T+组,31例) vs 未溶栓(T-组,41例)。
- 主要终点:90天生存率两组无差异(39% vs 46%,log-rank检验,p=0.31)。
- 次要终点:严重出血发生率无差异(61% vs 59%,p=1);T+组ECMO前心脏骤停更多(94% vs 67%,p=0.02)。
- 随访:25/28例患者在中位69(52-95)个月时随访,长期生活质量可接受,无慢性血栓栓塞性肺动脉高压。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,近期全身溶栓作为单一参数不应被视为高危肺栓塞VA-ECMO的禁忌症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Despite systemic thrombolysis, a few patients with high-risk pulmonary embolism (PE) remain hemodynamically unstable. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a considerable lifesaving therapy but systemic thrombolysis before cannulation could carry a high risk of hemorrhage and alter the prognosis.
METHODS: Between June 2012 and June 2023, we retrospectively analyzed from three intensive care units in Sorbonne University, ECMO-related complications and 90-day mortality for high-risk PE patients who received ECMO without previous systemic thrombolysis compared to those cannulated after systemic thrombolysis failure. Hospital discharge survivors were assessed for long-term health-related quality of life and echocardiographic evaluations.
RESULTS: 72 high-risk PE patients [median age 48 (37-61) years, Simplified Acute Physiology Score II (SAPS II) 74 (60-85)] were placed on VA-ECMO for 5 (5-7) days. 31 (43%) patients underwent pre-ECMO thrombolysis (thrombolysis ECMO group, T +) compared to 41 patients (57%, no thrombolysis ECMO group, T-). There was more pre-ECMO cardiac arrest in the thrombolysis ECMO group (94% vs. 67%, p = 0.02). Ninety-day survival was not different between groups (39% vs 46%, log-rank test, p = 0.31). There was no difference in severe hemorrhages (61% vs 59%, p = 1). Twenty-five over 28 patients attended follow-up at a median time of 69 (52-95) months. Long-term quality of life was acceptable and none of them experienced chronic thromboembolic pulmonary hypertension.
CONCLUSIONS: Ninety-day survival and bleeding events rates did not differ in patients treated with VA-ECMO after systemic thrombolysis compared to those who were not. Recent systemic thrombolysis, as a single parameter, should not be considered as a contraindication for VA-ECMO in high-risk PE.
参考来源
- Levy D, Saura O, Passarelli MT, et al. Thrombolysis before venoarterial ECMO for high-risk pulmonary embolism: a retrospective cohort study. Intensive Care Med. 2024. PMID: 38913095. doi:10.1007/s00134-024-07501-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。